Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
PLYMOUTH, Minn., July 6, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that it has reached an agreement with the plaintiffs to settle the...
PLYMOUTH, Minn., June 21, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV), a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted...
Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: BULL & LIFSHITZ, LLP ANNOUNCES INVESTIGATION OF...
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed acquisition of Ev3 Inc.(NASDAQ: EVVV) (referred to as...
Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of ev3 Inc...
Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of ev3 Inc. (“ev3" or the “Company”) (NASDAQ:EVVV), related...
Levi & Korsinsky is investigating the Board of Directors of ev3, Inc. (“ev3” or the “Company”) (NasdaqGS: EVVV) for possible breaches of fiduciary duty and other violations of...
Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of ev3 Inc. (“ev3” or the “Company”) (Nasdaq:EVVV) arising from the Company’s announcement...
Kendall Law Group, a national securities firm, is investigating ev3, Inc. (NASDAQ: EVVV) for shareholders in connection with the proposed sale of ev3 to Covidien, plc. (NYSE:...
Tripp Levy PLLC announces an investigation into the proposed acquisition of ev3, Inc. (NASDAQ: EVVV). On June 1, 2010, Covidien PLC announced that it is proposing to acquire all...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
